MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
Cambium Medical Technologies
Attachments
Regenerative Therapies through Novel Human Platelets - Cambium Medical Technologies
Parents
*Architects: Ophthalmology, Optometry & Ocular Health (BioPharmaceuticals & Biotechnology)
*Architects: Regenerative Medicine
*Industry: Georgia
FDA _ Orphan Drug Designation
Children
2017: Cambium Secures $5 Million in Series A Funding
2020: Cambium Announces Orphan Drug Designation for Dry Eye Indication
Atlanta, Georgia
Cambium Medical Technologies (“Improving quality of life--from within“) provides Elate Ocular®, biologic eye drops to treat dry eye disease.
Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets.
Founded 2013
The treatment, with five issued patents (US, China, Japan, Australia and EU), represents the company’s initial biologic product.
Jumps
AventaCell Biomedical Corporation, Ltd
Emory University